Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 11:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Whole blood Clear all
Terminated Phase 3 Interventional Results available

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

NCT04410445
View directory record Official record
Conditions
Melanoma, Melanoma Stage III, Melanoma Stage IV, Melanoma (Skin)
Interventions
Bempegaldesleukin, Nivolumab
Biological
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
765 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
62
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Anaheim, California + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Sep 28, 2026, 11:15 PM EDT
Active, not recruiting Phase 2 Interventional

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

NCT05638295
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Panitumumab, Sotorasib
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
180
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 135 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 28, 2026, 11:15 PM EDT
Terminated Phase 1 Interventional

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

NCT05909995
View directory record Official record
Conditions
Melanoma, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC), Microsatellite Instability - High (MSI-H), Mismatch Repair Deficient (dMMR), Colorectal Carcinoma (CRC)
Interventions
INCB 99280 with Ipilimumab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Sep 28, 2026, 11:15 PM EDT
Not listed No phase listed Observational

Change in Antibody Levels Following SARS-CoV-2 (Covid-19) Vaccinations

NCT04944095
View directory record Official record
Conditions
Covid-19, Subjects Vaccinated Against Covid-19
Interventions
Change in SARS-CoV-2 Antibody Levels
Other
Lead sponsor
Dr. Sidney J. Stohs
Other
Eligibility
55 Years and older
Enrollment
10,000 participants
Timeline
2021 – 2024
U.S. locations
1
States / cities
Southlake, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2022 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Phase 2 Interventional Results available

Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma

NCT00891839
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Bendamustine, Rituximab
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
11
States / cities
Fountain Valley, California • Los Angeles, California • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

NCT02713867
View directory record Official record
Conditions
Lung Cancer
Interventions
Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
77
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 70 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Phase 2 Interventional

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

NCT00004900
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, anastrozole, carboplatin, cisplatin, cyclophosphamide, etoposide, thiotepa, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 65 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

NCT04349267
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
BMS-986315, nivolumab, cetuximab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Sioux Falls, South Dakota • Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Not applicable Interventional

Health Literacy-Focused Program to Improve Blood Pressure Control in Korean Americans

NCT00406614
View directory record Official record
Conditions
Hypertension
Interventions
Health Literacy-Focused High Blood Pressure Intervention
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
60 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Ellicott City, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Sep 28, 2026, 11:15 PM EDT
Enrolling by invitation Not applicable Interventional

The Use of Focused Ultrasound and DCE K-trans Imaging to Evaluate Permeability of the Blood-Brain Barrier

NCT04063514
View directory record Official record
Conditions
Low Grade Glioma of Brain
Interventions
Focused Ultrasound
Other
Lead sponsor
Neurological Associates of West Los Angeles
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Sep 28, 2026, 11:15 PM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer

NCT02506114
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
PROSTVAC V/F, Ipilimumab
Biological · Drug
Lead sponsor
Lawrence Fong
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Sep 28, 2026, 11:15 PM EDT
Recruiting Phase 2 Interventional

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

NCT07605416
View directory record Official record
Conditions
Plasma Cell Leukemia
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, Fludeoxyglucose F-18, Lenalidomide, Magnetic Resonance Imaging, Melphalan, Plerixafor, Positron Emission Tomography, Recombinant Granulocyte Colony-Stimulating Factor, Stem Cell Isolation, Teclistamab, Transthoracic Echocardiography Test
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
7
States / cities
Middletown, New Jersey • Montvale, New Jersey • Buffalo, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 28, 2026, 11:15 PM EDT
Recruiting Phase 1 Interventional

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT05967416
View directory record Official record
Conditions
Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma
Interventions
SIRPant-M, External-beam radiotherapy (XRT)
Biological · Radiation
Lead sponsor
SIRPant Immunotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Duarte, California • Hackensack, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Sep 28, 2026, 11:15 PM EDT
Completed No phase listed Observational

Evaluating Multiple Sclerosis Patients ShOWing A GEnomic Signature of Therapy Response

NCT03316404
View directory record Official record
Conditions
Multiple Sclerosis, MS
Interventions
Not listed
Lead sponsor
DxTerity Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
1,168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Compton, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 28, 2026, 11:15 PM EDT
Recruiting Phase 2 Interventional

Cord Blood Transplant in Adults With Blood Cancers

NCT05884333
View directory record Official record
Conditions
Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndromes (MDS), Myeloproliferative Disorder, Non-Hodgkin's Lymphoma
Interventions
Conditioning Chemotherapy, Cord blood graft
Drug · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 28, 2026, 11:15 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Salt and Gut Study

NCT04958148
View directory record Official record
Conditions
High Blood Pressure
Interventions
Salt pills, Placebo pills
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 11, 2021 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Phase 1 Interventional

Trial of eRapa in Prostate Cancer Patients

NCT03618355
View directory record Official record
Conditions
Prostate Cancer
Interventions
eRapa (encapsulated rapamycin)
Drug
Lead sponsor
Rapamycin Holdings, Inc. dba Emtora Biosciences
Industry
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Phase 2 Interventional Results available

Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)

NCT00206726
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
Alemtuzumab plus Fludarabine
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
27
States / cities
Birmingham, Alabama • Berkeley, California • Burbank, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2016 · Synced Sep 28, 2026, 11:15 PM EDT
Recruiting Phase 1 Interventional

Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors

NCT05901285
View directory record Official record
Conditions
Advanced Solid Tumor, Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab
Interventions
VAX014, Nivolumab or pembrolizumab
Drug · Combination Product
Lead sponsor
Vaxiion Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Tucson, Arizona • Denver, Colorado • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 28, 2026, 11:15 PM EDT
Recruiting Not applicable Interventional

Time Restricted Eating for the Improvement of Outcomes in Patients With Stage I-III Breast Cancer Receiving Chemotherapy Before Surgery

NCT05327608
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Invasive Breast Carcinoma
Interventions
Short-Term Fasting, Chemotherapy, Biospecimen Collection, Questionnaire Administration
Other · Drug · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Cherry Hill, New Jersey • Sewell, New Jersey • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 28, 2026, 11:15 PM EDT
Recruiting No phase listed Observational

A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis

NCT04372108
View directory record Official record
Conditions
Crohn Disease, Colitis, Ulcerative
Interventions
Ustekinumab, Other Biologic Therapies
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,536 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of a Personalized vs. Standard Approach to Weight Loss Recommendations

NCT04639076
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Behavioral Weight Loss Program, Personalized Behavioral Weight Loss Program
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
20 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Sep 28, 2026, 11:15 PM EDT
Enrolling by invitation Not applicable Interventional

Using Remote Monitoring to Address Health Disparities in Type 2 Diabetes

NCT06517576
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Blood glucose monitor with Digital Platform and Health Coaching, Continuous glucose monitor, Usual Care
Device · Other
Lead sponsor
Lawndale Christian Health Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Not applicable Interventional

Measuring Changes in Body Composition and Physical Function in Patients With Childhood Cancers

NCT05823740
View directory record Official record
Conditions
Cancer, Malignant Neoplasm
Interventions
Bioelectrical impedance Analysis (BIA), D3-Creatine Dilution (D3Cr), 6-Minute Walk Test (6MWT), Timed Up and Go (TUG), 30-second Sit-to-Stand (STS), Hand Grip Strength (GS), PBTL p16 expression, CT, MR and PET Imaging
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
8 Years to 21 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 28, 2026, 11:15 PM EDT